Chemotherapy for GI Cancer: Genetic Testing Guide
Genetic testing for Gastrointestinal cancers Reduces Chemotherapy Side Effects
Nearly 300,000 Americans receive a diagnosis of gastrointestinal (GI) cancer annually, including colorectal cancer, the third most common cancer in the US. Standard chemotherapy protocols often employ a “one-size-fits-all” approach to dosing, failing to account for individual genetic variations that impact drug metabolism. emerging research demonstrates that pharmacogenomic testing – analyzing how genes affect a person’s response to drugs - can considerably improve patient safety and treatment outcomes.
Understanding the Role of Pharmacogenomics in Cancer treatment
Pharmacogenomics, a field pioneered at institutions like the Penn Medicine Center for Genomic Medicine, explores the influence of genetic makeup on drug response. This personalized approach to medicine aims to optimize drug selection and dosage based on an individual’s genetic profile, maximizing effectiveness while minimizing adverse effects. This is notably crucial in chemotherapy, where the therapeutic window - the difference between a beneficial dose and a toxic dose – can be narrow.
Researchers are increasingly focused on identifying genetic variants that affect how patients process common chemotherapy drugs. This allows clinicians to proactively adjust treatment plans, leading to more effective and safer care.
key Genes impacting Chemotherapy Response: DPYD and UGT1A1
A recent study highlighted the importance of analyzing variants in two specific genes: DPYD and UGT1A1. These genes play critical roles in metabolizing widely used chemotherapy drugs.
DPYD and Fluoropyrimidines
The DPYD gene provides instructions for making an enzyme essential for breaking down fluoropyrimidines,a class of drugs frequently used to treat GI cancers. Approximately 5-8% of the population carries DPYD variants that reduce the enzyme’s activity. this impaired metabolism can cause fluoropyrimidines to accumulate to toxic levels, leading to severe side effects such as:
Reduced blood cell production (myelosuppression)
mouth sores (mucositis)
Hand-foot syndrome (palmar-plantar erythrodysesthesia)
UGT1A1 and Irinotecan
The UGT1A1 gene influences how the body processes irinotecan, another vital chemotherapy drug for GI cancers. Certain UGT1A1 variants can slow down drug metabolism, increasing the risk of:
Severe diarrhea
Low white blood cell counts (neutropenia)
Identifying these genetic variations allows oncologists to proactively adjust irinotecan dosages, preventing debilitating side effects without compromising the drug’s effectiveness.
Study Demonstrates Benefits of Genetic Testing
A prospective clinical trial conducted at three University of pennsylvania Health System cancer care sites enrolled 517 GI cancer patients initiating chemotherapy with fluoropyrimidine or irinotecan. 288 patients underwent blood tests to identify DPYD and UGT1A1 variants.
The results were compelling:
Reduced Adverse Events: Among 16 patients with identified genetic variants who received dose reductions based on testing, 38% experienced severe treatment-related adverse events. This contrasted sharply with the 65% experiencing severe side effects in a control group of 17 patients with the same variants who received standard doses without prior testing.
Dosage Adjustments: The tested group required significantly fewer changes to their treatment dosage and frequency (38% vs. 76%).
Treatment Continuations: Fewer patients in the tested group had to discontinue treatment altogether (31% vs. 47%).
These findings underscore the potential of precision medicine, guided by pharmacogenomic testing, to enhance patient safety and improve treatment outcomes in GI cancer. The study demonstrates a clear clinical benefit to proactively identifying and addressing genetic predispositions to chemotherapy-related toxicities.
Future Implications and Access to Testing
This research, funded by the Penn Center for Precision Medicine and the National Institute of Health (TL1TR001880), paves the way for broader implementation of pharmacogenomic testing in GI cancer care. Increased accessibility to testing and integration of results into clinical decision-making will be crucial for realizing the full benefits of personalized chemotherapy.
further research is ongoing to identify additional genetic markers that influence drug response, expanding the scope of precision oncology and ultimately improving the lives of patients battling gastrointestinal cancers.
Sources:
University of Pennsylvania School of Medicine. (2024, February 29). Genetic testing lowers risks from chemo for GI cancer.[https://www.pennmedicine.org/news/genetic-testing-lowers-risks-from